GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (NAS:MRUS) » Definitions » Cyclically Adjusted PS Ratio

Merus NV (Merus NV) Cyclically Adjusted PS Ratio : 42.37 (As of May. 01, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Merus NV Cyclically Adjusted PS Ratio?

As of today (2024-05-01), Merus NV's current share price is $44.91. Merus NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $1.06. Merus NV's Cyclically Adjusted PS Ratio for today is 42.37.

The historical rank and industry rank for Merus NV's Cyclically Adjusted PS Ratio or its related term are showing as below:

MRUS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 26.91   Med: 41.8   Max: 48.89
Current: 42.75

During the past years, Merus NV's highest Cyclically Adjusted PS Ratio was 48.89. The lowest was 26.91. And the median was 41.80.

MRUS's Cyclically Adjusted PS Ratio is ranked worse than
91.55% of 509 companies
in the Biotechnology industry
Industry Median: 5.4 vs MRUS: 42.75

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Merus NV's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.155. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.06 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Merus NV Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Merus NV's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus NV Cyclically Adjusted PS Ratio Chart

Merus NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 26.06

Merus NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 26.06

Competitive Comparison of Merus NV's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Merus NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merus NV's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Merus NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Merus NV's Cyclically Adjusted PS Ratio falls into.



Merus NV Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Merus NV's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=44.91/1.06
=42.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merus NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Merus NV's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.155/126.4000*126.4000
=0.155

Current CPI (Dec. 2023) = 126.4000.

Merus NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.000 98.360 0.000
201406 0.000 99.240 0.000
201409 0.026 99.960 0.033
201412 0.031 99.050 0.040
201503 0.004 99.750 0.005
201506 0.080 100.230 0.101
201509 0.007 100.500 0.009
201512 0.001 99.730 0.001
201603 0.004 100.310 0.005
201606 0.018 100.260 0.023
201609 0.062 100.570 0.078
201612 -0.006 100.710 -0.008
201703 0.221 101.440 0.275
201706 0.321 101.370 0.400
201709 0.345 102.030 0.427
201712 0.374 101.970 0.464
201803 0.579 102.470 0.714
201806 0.328 103.100 0.402
201809 0.333 103.950 0.405
201812 0.521 103.970 0.633
201903 0.378 105.370 0.453
201906 0.272 105.840 0.325
201909 0.348 106.700 0.412
201912 0.292 106.800 0.346
202003 0.218 106.850 0.258
202006 0.209 107.510 0.246
202009 0.295 107.880 0.346
202012 0.301 107.850 0.353
202103 0.231 108.870 0.268
202106 0.323 109.670 0.372
202109 0.355 110.790 0.405
202112 0.355 114.010 0.394
202203 0.268 119.460 0.284
202206 0.291 119.050 0.309
202209 0.143 126.890 0.142
202212 0.230 124.940 0.233
202303 0.291 124.720 0.295
202306 0.217 125.830 0.218
202309 0.205 127.160 0.204
202312 0.155 126.400 0.155

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Merus NV  (NAS:MRUS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Merus NV Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Merus NV's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus NV (Merus NV) Business Description

Industry
Traded in Other Exchanges
Address
Uppsalalaan 17, Utrecht, NLD, 3584 CT
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Executives
Harry Shuman officer: Chief Accounting Officer C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Peter B. Silverman officer: EVP & General Counsel C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Sven Ante Lundberg director, officer: President, CEO & PFO C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Kruif John De officer: Chief Technology Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Paolo Pucci director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Len Kanavy director C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Maxine Gowen director
Anand Mehra director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Victor Sandor director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Mark T Iwicki director 84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Gregory D Perry director C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Geuijen Cecile A W officer: SVP & Chief Scientific Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584CM
Andrew Joe officer: SVP, CMO C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Mark Throsby officer: EVP & Chief Scientific Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM